Cardiology overview prevention: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
No edit summary
Replaced content with "{{Cardiology overview}} {{CMG}} ==References== {{Reflist|2}} {{WS}} {{WH}}"
 
(One intermediate revision by the same user not shown)
Line 2: Line 2:
{{CMG}}
{{CMG}}


==Statin Therapy==
===Drug Interactions===
*[[Cyclosporin]] co-administration is associated with a higher rate of [[myositis]] among statin users as a result of inhibition of [[CYP3A4]]. The exception is [[pravastatin]] in which this is not a problem.
===Reducing non-myositis Muscle Pain==
* [[Coenzyme Q]] can be used to reduce the incidence of non-[[myositis]] muscle pain.  Several weeks of coenzyme Q should be given prior to trying the combination of the agent with statin therapy.


==References==
==References==

Latest revision as of 00:52, 4 November 2011

Cardiology Overview

Home

Acute Coronary Syndromes

Antiplatelets and antithrombins

Cardiomyopathy

Congenital heart disease

Electrophysiology

Heart failure

Hypertension

Imaging

Invasive cardiology

Pericardial disease

Peripheral arterial disease

Pharmacology

Pregnancy

Preoperative evaluation

Prevention

Pulmonary hypertension

Stable angina

Valvular heart disease

Venous thromboembolism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


References

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Cardiology_overview_prevention&oldid=612094"